ARTICLE | Clinical News
Cloretazine: Additional Phase II data
May 23, 2005 7:00 AM UTC
Vion Pharmaceuticals Inc. (VION), New Haven, Conn. Product: Cloretazine ( VNP40101M) Business: Cancer Molecular target: DNA Description: Sulfonyl hydrazine prodrug alkylating agent that also inhibits...